NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its quarterly earnings data on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to analysts' expectations of $3.23 million. Kalvista Pharmaceuticals had a negative net margin of 182.37% and a negative return on equity of 25.70%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

5 brokers have issued 12-month price objectives for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $32.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $30.40 in the next year. This suggests a possible upside of 102.5% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Media headlines about KALV stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totalling 734,400 shares, a drop of 10.9% from the October 31st total of 824,300 shares. Based on an average daily trading volume, of 121,300 shares, the days-to-cover ratio is presently 6.1 days. Currently, 5.8% of the company's shares are short sold. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Phibro Animal Health (PAHC), Odonate Therapeutics (ODT), TG Therapeutics (TGTX), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), ZIOPHARM Oncology (ZIOP), Amphastar Pharmaceuticals (AMPH), Achillion Pharmaceuticals (ACHN), G1 Therapeutics (GTHX), IGM Biosciences (IGMS), Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), XBiotech (XBIT), Homology Medicines (FIXX) and Flexion Therapeutics (FLXN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), Viking Therapeutics (VKTX), Brainstorm Cell Therapeutics (BCLI), BIOLINERX LTD/S (BLRX) and Progenics Pharmaceuticals (PGNX).

Kalvista Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (9.43%), Pictet Asset Management Ltd. (3.06%), State Street Corp (1.28%), Squarepoint Ops LLC (0.70%), Point72 Asset Management L.P. (0.49%) and Orbimed Advisors LLC (0.22%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

KALV stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P. and Barclays PLC. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Insider Buying and Selling for Kalvista Pharmaceuticals.

KALV stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Pictet Asset Management Ltd., Squarepoint Ops LLC, Orbimed Advisors LLC, State Street Corp and Tower Research Capital LLC TRC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $15.01.

Kalvista Pharmaceuticals has a market capitalization of $267.69 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]